Lump-sum cancer policies pay on diagnosis. Per-treatment cancer policies pay on each covered event during treatment. Those two sentences describe the same product category but produce completely different client outcomes, and most supplemental product presentations skip the distinction entirely.
A client who receives a lump-sum benefit on diagnosis day has cash in hand before the first chemotherapy session. A client on a per-treatment policy may accumulate more total benefit across a 6-month treatment protocol, or may receive almost nothing if the cancer is treated surgically in a single procedure. The right product depends on the client's cancer risk profile, their ACA plan structure, and how they would realistically use the benefit. Presenting only one product type without explaining the alternative is an incomplete recommendation.
Key Takeaways
- Lump-sum cancer policies pay once on initial diagnosis of an internal cancer. The client receives cash directly and can use it for anything: deductibles, lost wages, travel, or non-medical expenses.
- Per-treatment policies pay on each covered procedure or confinement. A client receiving 30 radiation treatments may receive a benefit for each one, but only if each treatment is a covered event under the policy's schedule.
- Cancer policies almost never cover skin cancer classified as non-melanoma. A client who receives a basal cell diagnosis will not receive a benefit from most standard cancer products.
- Recurrence benefits vary by product. Some per-treatment policies reset the benefit cap after a defined disease-free period of 5 to 10 years. Others count recurrence benefits toward a lifetime maximum.
- Both product types can pay alongside an ACA Marketplace plan. The ACA plan pays its share of covered medical costs; the cancer policy pays the client cash separately. There is no coordination-of-benefits requirement.
How lump-sum cancer policies work
A lump-sum cancer policy pays a fixed benefit upon initial diagnosis of a covered internal cancer. The benefit is paid directly to the client, not to a hospital or provider. The client can use it for any purpose: the ACA plan deductible, travel to a cancer center, lost wages during treatment, or household expenses during recovery. There is no itemized reimbursement process and no coordination with the ACA carrier.
Most policies offer face amounts between $10,000 and $50,000. Some carriers offer supplemental riders that pay an additional benefit on hospital confinement or surgery, but the primary value is the initial diagnosis payment. The policy pays once per lifetime for most cancers, with a separate recurrence benefit provision if the policy includes one.
The survival period clause is the key underwriting term to disclose. If the policy requires the insured to survive 30 days after diagnosis, a client diagnosed with stage IV pancreatic cancer has a meaningful probability of not reaching the payment date. That is a material fact in the product recommendation for clients with family history of aggressive cancers.
How per-treatment cancer policies work
Per-treatment policies pay a scheduled benefit for each covered medical event in the treatment protocol. Common covered events include surgery, each radiation treatment session, each chemotherapy infusion, inpatient hospitalization days, and sometimes bone marrow transplants or immunotherapy sessions. Each event triggers a payment according to the policy's benefit schedule.
A client who undergoes surgery plus 25 radiation treatments plus 6 chemotherapy cycles might receive a benefit on each of those 32 events. Depending on the policy's schedule, total benefits across that treatment path could exceed $10,000 to $20,000, potentially more than a comparable lump-sum product. A client who is diagnosed and treated with a single surgical excision of a small melanoma might receive only one benefit payment and find the product far less valuable than anticipated.
The limitation brokers frequently underexplain: the client must have covered events. A cancer diagnosed late, treated briefly, and resolved with one procedure produces minimal per-treatment benefits. The product pays most when the treatment timeline is longest.
Side-by-side comparison
| Feature | Lump-Sum | Per-Treatment |
|---|---|---|
| Trigger event | Initial diagnosis of covered cancer | Each covered treatment, surgery, or confinement |
| Typical benefit amount | $10,000 to $50,000 paid once | $100 to $500 per event; accumulates across treatment |
| Client flexibility | Cash paid directly; use for any purpose | Requires covered events to occur; amount tied to treatment path |
| Recurrence | Varies; most policies pay once per lifetime | Varies; some reset after disease-free period of 5 to 10 years |
| Best fit client profile | Clients needing income replacement or deductible coverage in a lump sum | Clients with extended treatment protocols and predictable covered events |
| Non-medical expense coverage | Yes — client controls cash use | Only if policy offers a separate cash allowance provision |
Illustrative. Policy terms, benefit schedules, and covered cancers vary by carrier and state. Review the specific policy form before presenting to a client.
What neither product covers
Non-melanoma skin cancer, carcinoma in situ, and pre-cancerous conditions are excluded or significantly reduced under most cancer products. Basal cell carcinoma and squamous cell carcinoma, which are by far the most common cancers diagnosed in the US each year, do not trigger a benefit in most standard cancer policies. This is a first-page disclosure to make with any client who asks whether the product covers skin cancer.
Neither product type replicates the cost-sharing structure of a health plan. The ACA plan handles the negotiated medical costs through its network. The cancer policy pays cash benefits on covered events, and the two function independently. The cancer policy benefit does not reduce the ACA plan deductible or coinsurance. A client on a Bronze plan who receives a $25,000 lump-sum cancer benefit still owes the Bronze plan deductible on the medical side.
Cross-sell with ACA Bronze plans
The supplemental cancer conversation most often surfaces in the context of an ACA Bronze plan recommendation. A Bronze plan with a $7,000 to $9,450 deductible in 2026 leaves a client fully exposed on cancer treatment costs until that deductible is met. The lump-sum cancer policy addresses that exposure in one payment. The per-treatment policy addresses it event by event.
The cross-sell math that works: a lump-sum cancer benefit of $25,000 at a premium of $40 to $60 per month for a 40-year-old converts the uncertainty of a cancer treatment cost into a predictable monthly premium. Compared to the cost difference between a Bronze and Silver plan net of APTC, the cross-sell often pencils out, particularly for clients above 200 percent FPL where Silver CSR tiers are no longer available. The supplemental insurance with a Bronze plan guide covers the broader cross-sell math for hospital indemnity alongside a high-deductible ACA plan.
For clients where the cancer concern is more acute than general supplemental coverage, the trigger-based comparison in the hospital indemnity vs critical illness vs accident insurance guide shows how the three supplemental trigger events differ, which matters when a client has specific conditions driving their coverage concern rather than a general supplemental budget.
Frequently asked questions about cancer insurance payout structures
Common questions from ACA brokers presenting supplemental cancer coverage.
Does a lump-sum cancer policy pay on any cancer diagnosis?
Most lump-sum cancer policies cover internal cancers that are invasive. Non-invasive cancers, including carcinoma in situ and most non-melanoma skin cancers, are excluded or paid at a reduced benefit amount. The specific list of covered cancers is in the policy's definition section, not the summary. A client with a family history of basal cell carcinoma will not receive a benefit from most standard cancer products for that specific condition. A client with a history of breast cancer screening concerns or colorectal family history, where an invasive internal cancer is the relevant risk, is a better fit for a standard lump-sum product. The broker's job is to read the definition section, not assume it covers what the name implies.
Can a client collect on a cancer policy if they already had cancer before purchasing it?
No. Cancer policies contain pre-existing condition exclusions. A client with a prior diagnosis will be excluded from coverage for that cancer type, and most policies exclude any cancer diagnosis for a period of 12 to 24 months after the policy issue date regardless of pre-existing conditions. A client who was successfully treated for cancer and has been in remission for 5 years may find some carriers will underwrite coverage with an exclusion rider, but the prior condition exclusion typically applies for the duration of the policy. Attempting to place cancer coverage for a client in active treatment is not appropriate and constitutes a material misrepresentation on the application.
How does a per-treatment cancer policy interact with an ACA Bronze plan?
The two products cover different cost layers without coordination. The ACA Bronze plan pays the carrier-negotiated rate for covered medical services after the client meets the deductible. The cancer policy pays cash directly to the client based on its own benefit schedule, regardless of what the ACA plan paid or did not pay. There is no coordination-of-benefits rule between a supplemental indemnity policy and an ACA Marketplace plan. The practical cross-sell: a client on a Bronze plan with a $7,000 deductible will owe the full network cost of cancer-related services until that deductible is met. A per-treatment policy that pays $200 per outpatient radiation treatment and $500 per surgery converts some of that deductible exposure into a known monthly premium. The net cost comparison, Bronze premium plus per-treatment premium vs a Silver plan with a lower deductible, drives the recommendation.
What is a survival period clause in a cancer policy?
A survival period clause requires that the insured survive a specified number of days after diagnosis before the benefit is paid. The typical window is 14 to 30 days. If the insured dies within the survival period after a cancer diagnosis, the full lump-sum benefit is not paid. Some policies have a reduced benefit for clients who do not survive the survival period; others pay nothing. For clients who have identified cancer as their primary concern because of family history of aggressive cancers with poor prognosis, the survival period clause is a material policy term to disclose before the purchase. A cancer policy that pays $25,000 on diagnosis is worth less than it appears if the covered condition has a significant probability of death before the survival period ends.
Does a cancer policy cover the cost of cancer screening?
Generally, no. Cancer policies pay benefits on diagnosis and treatment, not on screening. ACA Marketplace plans are required under the ACA to cover preventive screenings such as colonoscopies and mammograms at zero cost-sharing for most enrollees. The cancer policy supplements the treatment cost after a diagnosis, which the ACA plan then applies cost-sharing to. A client who is focused purely on the cost of routine screening should rely on their ACA plan's preventive care coverage rather than a supplemental cancer product. The cancer product conversation starts at diagnosis, not at prevention.
